Dilip Shanghvi, managing director of Sun Pharmaceuticals, which has faced recent scrutiny from the FDA over issues at its plants, said he is trying to streamline quality-control processes that were overtaken by the merger with Ranbaxy, reported The Economic Times.

• "All of a sudden, [following the merger] we became twice the size of the company," he stated, adding that this "crystallised the need for working towards a system, working towards technology emphasis on improving IT backgrounds, focussing on issues that have affected us and also others in the world in regarding quality."

• Shanghvi said "we require different organisation to manage the increasing complexity of managing our manufacturing sites."

• He added "the emphasis and focus was on common quality rather than country specific or geography specific quality. I think the objective is work towards enhancing our capabilities reaching towards global standard."

• Since the merger, the combined company has standardised its quality metrics across plants on various issues impacting product quality, but Shanghvi acknowledged that some concerns remain.